What records are connected here?
- Evidence lanes
- 3
- Source years
- 3
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2Evidence: Animal and lab onlyTissue repair and wound healing
Also called N-terminal acetylated 17-23 fragment of thymosin beta-41,2
TB-500 is a synthetic seven-amino-acid peptide copied from one segment of the natural protein thymosin beta-4. It is not the same substance as thymosin beta-4, and the research on it comes from animal and laboratory studies.2 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved product containing it in any of the countries it checked.2 FDA found no studies of TB-500 in people. One registered trial was listed as recruiting in its March 2026 registry record, with no results posted.2,5 FDA staff recommended against adding TB-500 to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.2,7,8
| What it is | A synthetic, N-acetylated peptide matching amino acids 17 to 23 (LKKTETQ) of thymosin beta-4. FDA’s substance registry notes that its identity record does not imply regulatory review or approval.1,2 |
|---|---|
| FDA status | Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,7,8 |
| Human evidence | None found by FDA. One Phase 1/2 trial was listed as recruiting in its March 2026 registry record, with no results posted.2,5 |
| Sport status | FDA’s briefing notes that TB-500 is on the World Anti-Doping Agency’s prohibited list under section S2.3, as FDA checked in February 2024.2 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
TB-500 is a synthetic peptide of seven amino acids, LKKTETQ, with an acetyl group added at one end. The sequence matches amino acids 17 to 23 of thymosin beta-4, a 43-amino-acid protein found throughout the body.2
Websites often call TB-500 a synthetic version of thymosin beta-4, but FDA’s briefing states that they are not the same substance.2
TB-500 appears to have first been made in 2003. A veterinary preparation appeared in 2011 and was marketed to boost performance in horse and greyhound racing. FDA could not identify any pharmacy that compounds it, and no outsourcing facility had reported compounding it.2
TB-500 contains the segment of thymosin beta-4 that binds actin, a protein that helps cells keep their shape and move. Researchers have proposed that this could help wound healing, but that has not been shown for TB-500.2
In a laboratory study, TB-500 itself did not speed the closing of scratch wounds in cultured cells. FDA states that it remains unknown whether TB-500 has wound-healing effects in living animals.2
Studies in horses and laboratory models show that TB-500 is broken down into several smaller fragments. Except for one, the effects of those fragments are unknown.2
There are none in FDA’s review. FDA evaluated TB-500 for wound healing and found no clinical studies or other human exposure data for it by any route.2
The three references submitted to FDA in support of TB-500 were studies of thymosin beta-4 in animals or the laboratory.2
FDA’s adverse-event search through March 2025 found no reports. A search of FDA’s food and supplement complaint system found two cases about a blend of TB-500 and BPC-157, without safety assessments.2
One Phase 1/2 trial in atherosclerotic cardiovascular disease and endothelial dysfunction was listed as recruiting in its March 23, 2026 registry record, with no results posted.5
Evidence-strength label: Animal and lab studies only. How this label is assigned
No. FDA’s May 2026 evaluation states that neither TB-500 free base nor TB-500 acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.2
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.7
FDA staff evaluated both forms of TB-500 for that list for wound healing and recommended against adding either. They cited poor chemical characterization, no human data on safety or effectiveness, a possible risk of immune reactions, and existing FDA-approved wound treatments.2
FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.4
HHS’s policy document states that TB-500 was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.4,8
FDA’s Pharmacy Compounding Advisory Committee discussed TB-500 on July 23, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.2,3,8
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.7,8
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For TB-500, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.8
HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates supply the quality test results FDA staff found missing, that use is now documented, and that FDA staff’s safety concerns are inferred rather than observed, pointing to human safety data on the parent protein. FDA staff had found no human data on TB-500 itself.2,8
The policy does not make TB-500 an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.7,8
Whether TB-500 has any benefit in people, or even promotes wound healing in animals: FDA found no human studies and no animal wound-healing studies of TB-500 itself.2
Its safety in people, including whether it can trigger immune reactions, and what its breakdown products do.2
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that TB-500 and thymosin beta-4 are often confused.2
Whether FDA’s rulemaking will add TB-500 to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.2,7,8
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for TB-500: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for TB-500 are the records PeptideScanner has selected and published, not every registration or paper about TB-500. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Evidence summary
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
FDA assessment dated May 15, 2026 · Read September 15, 2026 · Preserved version 1
FDA's assessment of TB-500 free base and TB-500 acetate for the nominated use of wound healing. The assessment was prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting. FDA document ↗
FDA describes TB-500 free base as an N-terminal acetylated seven-amino-acid fragment of thymosin beta-4. It also warns that the common name has been used for different substances. Findings about full-length thymosin beta-4 cannot be assumed to apply to this fragment. FDA pp. 7, 8 ↗
FDA reported that it did not identify clinical studies of TB-500 administered to people and found insufficient evidence to evaluate effectiveness for wound healing. The nomination's references concerned thymosin beta-4 rather than human administration of the specified fragment. FDA pp. 23, 24 ↗
FDA reported no identified human pharmacokinetic or clinical safety studies. Its FAERS search through March 26, 2025 found no reports, while a separate complaint system contained two reports about blended TB-500 and BPC-157 without safety assessments. These findings do not establish safety or adverse-event rates. FDA pp. 30, 31 ↗
This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.
Source: FDA briefing document for TB-500. SHA-256: 973cffba12fec26da77d67b3e08604500b754eaa48d15912acb9596f3090b5a4.
Reviewed 2026-09-19 · Preserved version 1
FDA’s July 2026 briefing defines TB-500 as an N-acetylated seven-amino-acid fragment of the 43-amino-acid thymosin beta-4. Results for the full-length molecule or an unacetylated fragment cannot automatically be assigned to TB-500. FDA PDF pp. 25 ↗
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
FDA reported no identified clinical information showing administration of the nominated TB-500 substances to patients for wound healing or another condition. This remains a dated, source-specific assessment. FDA PDF pp. 24 ↗
The briefing found no clinical pharmacokinetic studies and described reports involving blended TB-500/BPC-157 products without safety assessments. These do not establish a TB-500-specific safety profile. FDA PDF pp. 30, 31 ↗
FDA reported no identified nonclinical toxicity studies for the nominated free base or acetate. That missing evidence should not be interpreted as either demonstrated safety or proof of a specific human harm. FDA PDF pp. 30 ↗
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Source dated 2026-07-23; retrieved 2026-09-19.
SHA-256: 973cffba12fec26da77d67b3e08604500b754eaa48d15912acb9596f3090b5a4
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Open machine-readable coverage and record decisions →
Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.
32 retrieved · 0 included · 31 excluded · 1 awaiting a decision · 0 full-text appraisals
"TB-500"[Title/Abstract] OR "LKKTETQ"[Title/Abstract]
Retrieved 2026-09-15T13:04:53.361962+00:00 · HTTP 200 · SHA-256 d23131a6c1719d9bbc196f6b18320c0941ffd67bb517fe7974d1610837e0528b.
Retrieved 2026-09-15T13:04:55.026531+00:00 · HTTP 200 · SHA-256 8fb5c54503bf790a2568785c68300c63dd00e5dfd28876eaa3b00a6f4de1abcf.
Showing 25 of 32 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
products.active_ingredients.name:"TB-500"
Retrieved 2026-09-15T11:10:29.051067+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["TB-500", "N-terminal acetylated 17-23 fragment of thymosin beta-4"]
Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["TB-500", "N-terminal acetylated 17-23 fragment of thymosin beta-4"]
Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["TB-500", "N-terminal acetylated 17-23 fragment of thymosin beta-4"]
Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
"TB-500" OR "N-terminal acetylated 17-23 fragment of thymosin beta-4"
Retrieved 2026-09-15T11:27:07.321076+00:00 · HTTP 200 · SHA-256 17aa1ce59dbc05c7f5d07f5f7ddad1dbfe5678d01f319e9253be717ec5708438.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Living status brief
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 12, 2026
ClinicalTrials.gov record NCT07487363↗Added to PeptideScanner August 14, 2026Regulatory · added August 21, 2026
Federal Register notice 2026-07361↗Source date April 16, 2026Clinical trials · added August 14, 2026
ClinicalTrials.gov record NCT07487363↗Source date November 12, 2026Literature metadata · added August 10, 2026
PubMed record PMID 22962027↗Source date January 28, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.
1 public history versions connect to 1 of these trial records across 1 submitted years. Open the record-history collection →
0 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 4 selected records; the records remain visible as metadata observations.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
ClinicalTrials.gov posted a newer version of NCT07487363, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
0 with attributed title, venue, publication-date, and type metadata.
1 public history versions across these dated registry records; status labels apply only to each cited observation.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span February 8, 2018 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.↗
Regulatory
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
Regulatory
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 22962027 at 2026-07-30T16:30:49.822Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-09-11. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 23084823 at 2026-07-30T16:30:49.836Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-10-23. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 38382158 at 2026-07-30T18:48:13.580Z. PubMed recorded a metadata revision date of 2024-03-11 and an Entrez history date of 2024-02-21. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
ClinicalTrials.gov · Official source · Source checked August 14, 2026
Federal Register via GovInfo · Official source · Source checked August 21, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026